Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 5/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3825742 | 1.00 | CCR1 (0.44) | CCR1CHRM2CCR5VNN1RIPK1 | |
| SCHEMBL2675451 | 0.92 | CCR1 (0.42) | CCR1CHRM2CCR5VNN1RIPK1 | |
| SCHEMBL27608396 | 0.92 | CCR1 (0.51) | CCR1CHRM2CCR5VNN1RIPK1 | |
| SCHEMBL7688420 | 0.92 | CCR1 (0.51) | CCR1CHRM2CCR5VNN1RIPK1 | |
| SCHEMBL4389912 | 0.89 | CCR1 (0.35) | CCR1CHRM2CCR5 | |
| SCHEMBL2676714 | 0.88 | HTR3E (0.35) | CCR1CHRM2CCR5RIPK1SCN9A | |
| SCHEMBL6168934 | 0.87 | CCR1 (0.36) | CCR1CHRM2CCR5VNN1RIPK1 | |
| SCHEMBL2675071 | 0.87 | CCR1 (0.40) | CCR1CHRM2CCR5 | |
| SCHEMBL2677146 | 0.86 | RIPK1 (0.33) | CCR1CHRM2CCR5RIPK1 | |
| SCHEMBL6166473 | 0.85 | CCR1 (0.37) | CCR1CHRM2CCR5VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8257739-B2 | low-solubility drug (especially CCR-1 inhibitors) and a concentration-enhancing polymer; drug-rich regions are interspersed throughout drug-poor, polymer-rich regions; storage stability | BEND RESEARCH, INC. (US) | 2012-09-04 | — | — | US | claimed |
| EP-1931316-B1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID LABILE DRUGS | SOLVAY PHARM GMBH (DE) | 2010-02-17 | — | — | EP | claimed |
| EP-1404300-B1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | PFIZER PROD INC (US) | 2009-09-30 | — | — | EP | claimed |
| US-20060204577-A1 | Pharmaceutical Compositions of Drugs and Neutralized Acidic Polymers | PFIZER PRODUCTS INC. | 2006-09-14 | — | — | US | claimed |
| EP-1051405-B1 | NOVEL DIHYDROXYHEXANOIC ACID DERIVATIVES | PFIZER PROD INC (US) | 2006-08-23 | — | — | EP | claimed |
| EP-1558587-A1 | HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES AS IMMUNOMODULATORY AGENTS | Pfizer Products Inc. (US) | 2005-08-03 | — | — | EP | claimed |
| US-6858744-B2 | Dihydoxyhexanoic acid derivatives, their intermediates, and methods of making | PFIZER INC. (US) | 2005-02-22 | — | — | US | claimed |
| US-20040156905-A1 | Pharmaceutical compositions of semi-ordered drugs and polymers | PFIZER INC. | 2004-08-12 | — | — | US | claimed |
| US-20040097554-A1 | Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents | PFIZER INC | 2004-05-20 | — | — | US | claimed |
| WO-2004039787-A1 | HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES AS IMMUNOMODULATORY AGENTS | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | claimed |
| US-20040087571-A1 | Methods of using CCR1 antagonists as immunomodulatory agents | PFIZER INC | 2004-05-06 | — | — | US | claimed |
| US-20040019217-A1 | Dihydoxyhexanoic acid derivatives, their intermediates, and methods of making | PFIZER INC. | 2004-01-29 | — | — | US | claimed |
| US-6673801-B1 | TREATING MULTIPLE SCLEROSIS OR RHEUMATOID ARTHRITIS | PFIZER INC. | 2004-01-06 | — | — | US | claimed |
| WO-2003000235-A9 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | PFIZER PROD INC (US) | 2003-12-24 | — | — | WO | claimed |
| US-20030104063-A1 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers | LONZA BEND INC. | 2003-06-05 | — | — | US | claimed |
| US-20030091643-A1 | Amorphous mixture of acid sensitive drug and addition polymer; chemical resistance, stability | BEND RESEARCH, INC. | 2003-05-15 | — | — | US | claimed |
| US-20030054038-A1 | Pharmaceutical compositions of drugs and neutralized acidic polymers | BEND RESEARCH, INC. | 2003-03-20 | — | — | US | claimed |
| US-20030018033-A1 | Novel dihydroxyhexanoic acid derivatives | KATH JOHN CHARLES (US) | 2003-01-23 | — | — | US | claimed |
| EP-1051405-A2 | NOVEL DIHYDROXYHEXANOIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2000-11-15 | — | — | EP | claimed |
| WO-1999040061-A2 | NOVEL DIHYDROXYHEXANOIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-08-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030104063-A1 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers | ABCG2, ABCB1, MATR3 | CCR1 3503/4885CHRM2 590/4885CCR5 4342/4885 |
| US-20030054038-A1 | Pharmaceutical compositions of drugs and neutralized acidic polymers | PDE7A, CA6, PDE9A | CCR1 1188/4885CHRM2 2122/4885CCR5 975/4885 |
| US-20030018033-A1 | Novel dihydroxyhexanoic acid derivatives | HCAR1, HCAR2, SLC27A1 | CCR1 180/4885CHRM2 3772/4885CCR5 307/4885 |
| US-20040087571-A1 | Methods of using CCR1 antagonists as immunomodulatory agents | CCR1, CCR3, CCRL2 | CCR1 1/4885CHRM2 492/4885CCR5 10/4885 |
| US-20040156905-A1 | Pharmaceutical compositions of semi-ordered drugs and polymers | ABCB1, ABCG2, PDE7A | CCR1 1295/4885CHRM2 2431/4885CCR5 2594/4885 |
| US-20030091643-A1 | Amorphous mixture of acid sensitive drug and addition polymer; chemical resistance, stability | ABCC1, ABCG2, PGD | CCR1 4570/4885CHRM2 1997/4885CCR5 4616/4885 |
| US-20060204577-A1 | Pharmaceutical Compositions of Drugs and Neutralized Acidic Polymers | PDE7A, CA6, PDE9A | CCR1 1188/4885CHRM2 2122/4885CCR5 975/4885 |
| US-20040019217-A1 | Dihydoxyhexanoic acid derivatives, their intermediates, and methods of making | HAAO, HDHD5, HPD | CCR1 3063/4885CHRM2 4552/4885CCR5 1823/4885 |
| US-20040097554-A1 | Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents | CCR1, HCAR1, CCR3 | CCR1 1/4885CHRM2 143/4885CCR5 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.